Sex differences in CSF biomarkers of Alzheimer’s disease

Michelle M. Mielke

doi:10.1016/B978-0-12-819344-0.00012-0

Sex differences in CSF biomarkers of Alzheimer’s disease

Michelle M. Mielke

Quantitative Health Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The development of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and related disorders is rapidly progressing. Although the use of precision medicine methods has contributed to enhanced understanding of the AD pathophysiological changes and development of assays, one aspect not commonly considered is sex and gender differences. There are several ways in which sex can affect the measurement or interpretation of AD-related CSF biomarkers, including sex differences in biomarker concentrations and sex differences in the diagnosis or prognosis of the biomarker. This chapter highlights the impetus to consider sex differences in the development and interpretation of clinical assays for CSF biomarkers of AD.

Original language	English (US)
Title of host publication	Sex and Gender Differences in Alzheimer’s Disease
Publisher	Elsevier
Pages	107-123
Number of pages	17
ISBN (Electronic)	9780128193440
DOIs	https://doi.org/10.1016/B978-0-12-819344-0.00012-0
State	Published - Jan 1 2021

Keywords

Alzheimer’s disease
Amyloid-beta
Cerebrospinal fluid
Dementia
Sex differences
Tau

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-12-819344-0.00012-0

Cite this

@inbook{7264984cec7f457c954d51332374ffcd,

title = "Sex differences in CSF biomarkers of Alzheimer{\textquoteright}s disease",

abstract = "The development of cerebrospinal fluid (CSF) biomarkers for Alzheimer{\textquoteright}s disease (AD) and related disorders is rapidly progressing. Although the use of precision medicine methods has contributed to enhanced understanding of the AD pathophysiological changes and development of assays, one aspect not commonly considered is sex and gender differences. There are several ways in which sex can affect the measurement or interpretation of AD-related CSF biomarkers, including sex differences in biomarker concentrations and sex differences in the diagnosis or prognosis of the biomarker. This chapter highlights the impetus to consider sex differences in the development and interpretation of clinical assays for CSF biomarkers of AD.",

keywords = "Alzheimer{\textquoteright}s disease, Amyloid-beta, Cerebrospinal fluid, Dementia, Sex differences, Tau",

author = "Mielke, {Michelle M.}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-819344-0.00012-0",

language = "English (US)",

pages = "107--123",

booktitle = "Sex and Gender Differences in Alzheimer{\textquoteright}s Disease",

publisher = "Elsevier",

}

TY - CHAP

T1 - Sex differences in CSF biomarkers of Alzheimer’s disease

AU - Mielke, Michelle M.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - The development of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and related disorders is rapidly progressing. Although the use of precision medicine methods has contributed to enhanced understanding of the AD pathophysiological changes and development of assays, one aspect not commonly considered is sex and gender differences. There are several ways in which sex can affect the measurement or interpretation of AD-related CSF biomarkers, including sex differences in biomarker concentrations and sex differences in the diagnosis or prognosis of the biomarker. This chapter highlights the impetus to consider sex differences in the development and interpretation of clinical assays for CSF biomarkers of AD.

AB - The development of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and related disorders is rapidly progressing. Although the use of precision medicine methods has contributed to enhanced understanding of the AD pathophysiological changes and development of assays, one aspect not commonly considered is sex and gender differences. There are several ways in which sex can affect the measurement or interpretation of AD-related CSF biomarkers, including sex differences in biomarker concentrations and sex differences in the diagnosis or prognosis of the biomarker. This chapter highlights the impetus to consider sex differences in the development and interpretation of clinical assays for CSF biomarkers of AD.

KW - Alzheimer’s disease

KW - Amyloid-beta

KW - Cerebrospinal fluid

KW - Dementia

KW - Sex differences

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85128038635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128038635&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-819344-0.00012-0

DO - 10.1016/B978-0-12-819344-0.00012-0

M3 - Chapter

AN - SCOPUS:85128038635

SP - 107

EP - 123

BT - Sex and Gender Differences in Alzheimer’s Disease

PB - Elsevier

ER -

Sex differences in CSF biomarkers of Alzheimer’s disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this